查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589575

阿黴素市場：按配方、分銷管道和應用分類 - 2025-2030 年全球預測

Doxorubicin Market by Drug Formulation (Doxorubicin Injection, Lyophilized Powder), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

根據預測，2023年阿黴素市值為23.9億美元，預計到2024年將達到26.5億美元，複合年成長率為10.82%，到2030年將達到49.2億美元。

阿黴素是一種化療藥物，屬於細胞週期蛋白類藥物，主要用於治療多種癌症類型，包括乳癌、卵巢癌和淋巴瘤等。它在癌症治療中的重要作用凸顯了對有效藥物傳遞和降低心臟毒性的需求，從而推動了對脂質體製劑和標靶治療方案的研究。在癌症發病率上升和生物技術進步的推動下，癌症治療市場強勁成長，凸顯了開發標靶治療和毒性較低製劑的巨大機會。新興市場因醫療基礎設施的發展而作為潛在的擴張領域佔據重要地位。但市場開拓受到副作用嚴重、監管要求嚴格、開發核准成本高等因素制約，部分地區准入和購買受到限制。

主要市場統計
基準年[2023] 23.9億美元
預測年份 [2024] 26.5億美元
預測年份 [2030] 49.2億美元
複合年成長率（%） 10.82%

該行業的創新時機已經成熟，趨勢是探索新型藥物的聯合治療，以提高療效並減少副作用。利用奈米技術改進遞送系統以增加腫瘤部位的藥物濃度，同時降低全身毒性也是一個有前景的研究途徑。此外，結合生物標記主導的治療計劃來最佳化藥物療效的個人化醫療方法也越來越受歡迎。儘管有這些進步的趨勢，但學名藥藥和生物相似藥的競爭、分銷挑戰和智慧財產權障礙等問題仍然是市場快速成長的障礙。

總之，持續的研發投資、開發創新的輸送機制以及建立策略夥伴關係對於最大限度地發揮阿黴素的市場潛力至關重要。公司可以考慮專注於精準醫療和聯合治療以脫穎而出。這些進步不僅可以改善治療結果，還可以提高市場滲透率並使治療組合多樣化，以有效應對競爭格局。這些策略，加上解決監管和成本挑戰，可能會重新定義阿黴素市場的業務成長前景。

市場動態：揭示快速發展的阿黴素市場的關鍵市場洞察

阿黴素市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球癌症發生率增加
    • 政府核准使用阿黴素治療某些疾病
    • 加大力度提高意識和藥物供應
  • 市場限制因素
    • 法律規範的變化
  • 市場機會
    • 持續研發以發現及開發新藥
    • 政府對癌症治療和預防的支持
  • 市場問題
    • 藥物的嚴重副作用

波特的五力：駕馭阿黴素市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解阿黴素市場的外部影響

外部宏觀環境因素在塑造阿黴素市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解阿黴素市場的競爭格局

對多柔比星市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：阿黴素市場供應商的績效評估

FPNV定位矩陣是評估阿黴素市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃阿黴素市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對阿黴素市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率上升
      • 政府核准使用阿黴素治療某些疾病
      • 加強努力提高認知並改善藥物可得性
    • 抑制因素
      • 法規結構的變化
    • 機會
      • 持續研發以發現及開發新藥
      • 政府對癌症治療和預防的支持
    • 任務
      • 藥物的嚴重副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章阿黴素市場：按配方

  • 介紹
  • 阿黴素注射液
  • 凍乾粉

第7章阿黴素市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章阿黴素市場：依應用分類

  • 介紹
  • 骨癌
  • 乳癌
  • 子宮內膜癌
  • 胃癌
  • 卡波西氏肉瘤
  • 腎癌
  • 白血病
  • 肝癌
  • 多發性骨髓瘤
  • 卵巢癌

第9章 美洲阿黴素市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太阿黴素市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲阿黴素市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie, Inc.
  • Cadila Pharmaceuticals Ltd.
  • Changzhou Kinyond Pharmaceutical Co., Ltd
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Getwell Oncology Pvt Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Limited
  • Ipsen SA
  • Janssen Global Services, LLC By Johnson & Johnson Services, Inc.
  • LGM Pharma, LLC
  • Manus Aktteva Biopharma LLP
  • Meiji Holdings Co., Ltd.
  • Merrimack Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SRS pharmaceuticals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals
  • Thymoorgan Pharmazie GmbH
  • TTY Biopharma
Product Code: MRR-ED54C46E8664

The Doxorubicin Market was valued at USD 2.39 billion in 2023, expected to reach USD 2.65 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 4.92 billion by 2030.

Doxorubicin, a chemotherapeutic agent, falls within the anthracycline drug class and is utilized primarily for treating several cancer types, notably breast cancer, ovarian cancer, and lymphoma. Its pivotal role in oncology emphasizes the need for efficient drug delivery and reduced cardiotoxicity, bolstering research in liposomal formulations and targeted therapy options. The cancer therapeutics market's robust growth, fueled by increasing cancer prevalence and advancements in biotechnology, highlights noteworthy opportunities in developing targeted and less toxic doxorubicin formulations. Emerging markets, due to evolving healthcare infrastructures, represent significant potential expansion areas. However, market growth is tempered by factors such as significant side effects, stringent regulatory requirements, and high development and approval costs, leading to limited accessibility and affordability in some regions.

KEY MARKET STATISTICS
Base Year [2023] USD 2.39 billion
Estimated Year [2024] USD 2.65 billion
Forecast Year [2030] USD 4.92 billion
CAGR (%) 10.82%

The industry is seeing an inclination toward researching combination therapies where doxorubicin is paired with novel agents to enhance efficacy and reduce adverse reactions, thus presenting an area ripe for innovation. Leveraging nanotechnology to improve delivery systems and diminish systemic toxicity while enhancing drug concentration at tumor sites is another promising research avenue. Additionally, personalized medicine approaches, incorporating biomarker-driven treatment plans to optimize drug efficacy, are gaining traction. Despite these progressive trends, issues like competition from generic alternatives and biosimilars, distribution challenges, and intellectual property hurdles persist as barriers to swift market growth.

In conclusion, the onus lies on continuous R&D investments, innovative delivery mechanism development, and strategic partnerships to unleash doxorubicin's full market potential. Companies can consider focusing on precision medicine and combination therapies to stand out. These advancements can not only enhance therapeutic outcomes but also catalyze market penetration, diversifying therapeutic portfolios to withstand the competitive landscape effectively. Such strategies, coupled with addressing regulatory and cost challenges, could redefine business growth prospects in the doxorubicin market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Doxorubicin Market

The Doxorubicin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing cancer incidence rate worldwide
    • Government approvals for use of doxorubicin against certain disorders
    • Growing effort towards increasing awareness and drug availability
  • Market Restraints
    • Changing regulatory frameworks
  • Market Opportunities
    • Ongoing research and development for novel drug discovery and development
    • Supportive government initiatives for cancer treatment and prevention
  • Market Challenges
    • Serious side effects of the drug

Porter's Five Forces: A Strategic Tool for Navigating the Doxorubicin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Doxorubicin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Doxorubicin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Doxorubicin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Doxorubicin Market

A detailed market share analysis in the Doxorubicin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Doxorubicin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Doxorubicin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Doxorubicin Market

A strategic analysis of the Doxorubicin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Doxorubicin Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Cadila Pharmaceuticals Ltd., Changzhou Kinyond Pharmaceutical Co., Ltd, Cipla, Inc., Dr. Reddy's Laboratories Ltd., Getwell Oncology Pvt Ltd, Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Ipsen S.A., Janssen Global Services, LLC By Johnson & Johnson Services, Inc., LGM Pharma, LLC, Manus Aktteva Biopharma LLP, Meiji Holdings Co., Ltd., Merrimack Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., SRS pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Thymoorgan Pharmazie GmbH, and TTY Biopharma.

Market Segmentation & Coverage

This research report categorizes the Doxorubicin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Formulation, market is studied across Doxorubicin Injection and Lyophilized Powder.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Application, market is studied across Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Kaposi Sarcoma, Kidney Cancer, Leukemia, Liver Cancer, Multiple Myeloma, and Ovarian Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cancer incidence rate worldwide
      • 5.1.1.2. Government approvals for use of doxorubicin against certain disorders
      • 5.1.1.3. Growing effort towards increasing awareness and drug availability
    • 5.1.2. Restraints
      • 5.1.2.1. Changing regulatory frameworks
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for novel drug discovery and development
      • 5.1.3.2. Supportive government initiatives for cancer treatment and prevention
    • 5.1.4. Challenges
      • 5.1.4.1. Serious side effects of the drug
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Doxorubicin Market, by Drug Formulation

  • 6.1. Introduction
  • 6.2. Doxorubicin Injection
  • 6.3. Lyophilized Powder

7. Doxorubicin Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Pharmacy
  • 7.4. Retail Pharmacy

8. Doxorubicin Market, by Application

  • 8.1. Introduction
  • 8.2. Bone Sarcoma
  • 8.3. Breast Cancer
  • 8.4. Endometrial Cancer
  • 8.5. Gastric Cancer
  • 8.6. Kaposi Sarcoma
  • 8.7. Kidney Cancer
  • 8.8. Leukemia
  • 8.9. Liver Cancer
  • 8.10. Multiple Myeloma
  • 8.11. Ovarian Cancer

9. Americas Doxorubicin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Doxorubicin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Doxorubicin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Cadila Pharmaceuticals Ltd.
  • 3. Changzhou Kinyond Pharmaceutical Co., Ltd
  • 4. Cipla, Inc.
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Getwell Oncology Pvt Ltd
  • 7. Glenmark Pharmaceuticals Ltd.
  • 8. Intas Pharmaceuticals Limited
  • 9. Ipsen S.A.
  • 10. Janssen Global Services, LLC By Johnson & Johnson Services, Inc.
  • 11. LGM Pharma, LLC
  • 12. Manus Aktteva Biopharma LLP
  • 13. Meiji Holdings Co., Ltd.
  • 14. Merrimack Pharmaceuticals, Inc.
  • 15. Novartis AG
  • 16. Pfizer, Inc.
  • 17. SRS pharmaceuticals Pvt. Ltd.
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Teva Pharmaceuticals
  • 20. Thymoorgan Pharmazie GmbH
  • 21. TTY Biopharma

LIST OF FIGURES

  • FIGURE 1. DOXORUBICIN MARKET RESEARCH PROCESS
  • FIGURE 2. DOXORUBICIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DOXORUBICIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DOXORUBICIN MARKET DYNAMICS
  • TABLE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY DOXORUBICIN INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DOXORUBICIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DOXORUBICIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DOXORUBICIN MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DOXORUBICIN MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DOXORUBICIN MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DOXORUBICIN MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DOXORUBICIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DOXORUBICIN MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DOXORUBICIN MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 153. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2023